Mankind Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:54 pm

Quick Insight

Mankind Pharma Ltd, based in Okhla Industrial Estate, New Delhi, currently trades at a price of 2,502 with a market capitalization of 1,03,265 Cr. The company's P/E stands at 57.1, reflecting a premium valuation. Despite a respectable ROE of 13.9% and ROCE of 15.0%, the high price-to-book value of 6.98x may raise concerns about overvaluation. With a healthy operating profit margin of 26% and adequate interest coverage ratio of 8.28x, Mankind Pharma's financial health seems robust. However, the significant level of borrowings at ₹7,254 Cr and a relatively long cash conversion cycle of 108 days could pose liquidity challenges in the future, warranting careful monitoring by investors.

Competitors of Mankind Pharma Ltd

All Competitor Stocks of Mankind Pharma Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:25 am

Below is a detailed analysis of the quarterly data for Mankind Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 2,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,127.00 Cr. (Mar 2025) to 2,541.00 Cr., marking an increase of 414.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,868.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,650.00 Cr. (Mar 2025) to 1,868.00 Cr., marking an increase of 218.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 673.00 Cr.. The value appears strong and on an upward trend. It has increased from 477.00 Cr. (Mar 2025) to 673.00 Cr., marking an increase of 196.00 Cr..
• For OPM %, as of Jun 2025, the value is 26.00%. The value appears strong and on an upward trend. It has increased from 22.00% (Mar 2025) to 26.00%, marking an increase of 4.00%.
• For Other Income, as of Jun 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 219.00 Cr. (Mar 2025) to 64.00 Cr., marking a decrease of 155.00 Cr..
• For Interest, as of Jun 2025, the value is 147.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 162.00 Cr. (Mar 2025) to 147.00 Cr., marking a decrease of 15.00 Cr..
• For Depreciation, as of Jun 2025, the value is 97.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 105.00 Cr. (Mar 2025) to 97.00 Cr., marking a decrease of 8.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 494.00 Cr.. The value appears strong and on an upward trend. It has increased from 429.00 Cr. (Mar 2025) to 494.00 Cr., marking an increase of 65.00 Cr..
• For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be increasing, which may not be favorable. It has increased from 11.00% (Mar 2025) to 16.00%, marking an increase of 5.00%.
• For Net Profit, as of Jun 2025, the value is 413.00 Cr.. The value appears strong and on an upward trend. It has increased from 382.00 Cr. (Mar 2025) to 413.00 Cr., marking an increase of 31.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 10.00. The value appears strong and on an upward trend. It has increased from 9.27 (Mar 2025) to 10.00, marking an increase of 0.73.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 2:25 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:43 pm

Below is a detailed analysis of the balance sheet data for Mankind Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 14,599.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,663.00 Cr. (Mar 2024) to 14,599.00 Cr., marking an increase of 4,936.00 Cr..
• For Borrowings, as of Mar 2025, the value is 7,254.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 24.00 Cr. (Mar 2024) to 7,254.00 Cr., marking an increase of 7,230.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,934.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,790.00 Cr. (Mar 2024) to 1,934.00 Cr., marking an increase of 144.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 23,828.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,516.00 Cr. (Mar 2024) to 23,828.00 Cr., marking an increase of 12,312.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 3,471.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,552.00 Cr. (Mar 2024) to 3,471.00 Cr., marking a decrease of 81.00 Cr..
• For CWIP, as of Mar 2025, the value is 207.00 Cr.. The value appears to be declining and may need further review. It has decreased from 209.00 Cr. (Mar 2024) to 207.00 Cr., marking a decrease of 2.00 Cr..
• For Investments, as of Mar 2025, the value is 16,683.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,215.00 Cr. (Mar 2024) to 16,683.00 Cr., marking an increase of 12,468.00 Cr..
• For Other Assets, as of Mar 2025, the value is 3,467.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,540.00 Cr. (Mar 2024) to 3,467.00 Cr., marking a decrease of 73.00 Cr..
• For Total Assets, as of Mar 2025, the value is 23,828.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,516.00 Cr. (Mar 2024) to 23,828.00 Cr., marking an increase of 12,312.00 Cr..

Notably, the Reserves (14,599.00 Cr.) exceed the Borrowings (7,254.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Mankind Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 49.28. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 49.28, marking an increase of 1.53.
• For Diluted EPS (Rs.), as of Mar 25, the value is 49.20. This value is within the healthy range. It has increased from 47.68 (Mar 24) to 49.20, marking an increase of 1.52.
• For Cash EPS (Rs.), as of Mar 25, the value is 63.50. This value is within the healthy range. It has increased from 58.03 (Mar 24) to 63.50, marking an increase of 5.47.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 295.87. It has increased from 257.99 (Mar 24) to 295.87, marking an increase of 37.88.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 86.15. This value is within the healthy range. It has increased from 70.29 (Mar 24) to 86.15, marking an increase of 15.86.
• For PBIT / Share (Rs.), as of Mar 25, the value is 71.10. This value is within the healthy range. It has increased from 60.35 (Mar 24) to 71.10, marking an increase of 10.75.
• For PBT / Share (Rs.), as of Mar 25, the value is 60.69. This value is within the healthy range. It has increased from 59.52 (Mar 24) to 60.69, marking an increase of 1.17.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 48.45. This value is within the healthy range. It has increased from 48.09 (Mar 24) to 48.45, marking an increase of 0.36.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 48.25. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 48.25, marking an increase of 0.50.
• For PBDIT Margin (%), as of Mar 25, the value is 29.11. This value is within the healthy range. It has increased from 27.24 (Mar 24) to 29.11, marking an increase of 1.87.
• For PBIT Margin (%), as of Mar 25, the value is 24.03. This value exceeds the healthy maximum of 20. It has increased from 23.39 (Mar 24) to 24.03, marking an increase of 0.64.
• For PBT Margin (%), as of Mar 25, the value is 20.51. This value is within the healthy range. It has decreased from 23.06 (Mar 24) to 20.51, marking a decrease of 2.55.
• For Net Profit Margin (%), as of Mar 25, the value is 16.37. This value exceeds the healthy maximum of 10. It has decreased from 18.64 (Mar 24) to 16.37, marking a decrease of 2.27.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has decreased from 18.50 (Mar 24) to 16.30, marking a decrease of 2.20.
• For Return on Networth / Equity (%), as of Mar 25, the value is 13.89. This value is below the healthy minimum of 15. It has decreased from 20.43 (Mar 24) to 13.89, marking a decrease of 6.54.
• For Return on Capital Employeed (%), as of Mar 25, the value is 13.27. This value is within the healthy range. It has decreased from 24.56 (Mar 24) to 13.27, marking a decrease of 11.29.
• For Return On Assets (%), as of Mar 25, the value is 7.17. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 7.17, marking a decrease of 8.81.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.38, marking an increase of 0.38.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 0.59, marking an increase of 0.57.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.61. It has decreased from 0.95 (Mar 24) to 0.61, marking a decrease of 0.34.
• For Current Ratio (X), as of Mar 25, the value is 1.27. This value is below the healthy minimum of 1.5. It has decreased from 3.10 (Mar 24) to 1.27, marking a decrease of 1.83.
• For Quick Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has decreased from 2.37 (Mar 24) to 0.89, marking a decrease of 1.48.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.11. This value is below the healthy minimum of 4. It has decreased from 1.21 (Mar 24) to 1.11, marking a decrease of 0.10.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 8.28. This value is within the healthy range. It has decreased from 83.98 (Mar 24) to 8.28, marking a decrease of 75.70.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.64. This value is within the healthy range. It has decreased from 58.45 (Mar 24) to 5.64, marking a decrease of 52.81.
• For Enterprise Value (Cr.), as of Mar 25, the value is 108,171.91. It has increased from 91,239.85 (Mar 24) to 108,171.91, marking an increase of 16,932.06.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 8.83 (Mar 24) to 8.86, marking an increase of 0.03.
• For EV / EBITDA (X), as of Mar 25, the value is 30.43. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 30.43, marking a decrease of 1.97.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
• For Price / BV (X), as of Mar 25, the value is 6.98. This value exceeds the healthy maximum of 3. It has decreased from 9.83 (Mar 24) to 6.98, marking a decrease of 2.85.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness